Jiangsu Hengrui Medicine Co., Ltd.

Shanghai Stock Exchange 600276.SS

Jiangsu Hengrui Medicine Co., Ltd. Price to Sales Ratio (P/S) on January 14, 2025: 11.83

Jiangsu Hengrui Medicine Co., Ltd. Price to Sales Ratio (P/S) is 11.83 on January 14, 2025, a 0.37% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

Jiangsu Hengrui Medicine Co., Ltd. 52-week high Price to Sales Ratio (P/S) is 15.74 on October 08, 2024, which is 33.01% above the current Price to Sales Ratio (P/S).
Jiangsu Hengrui Medicine Co., Ltd. 52-week low Price to Sales Ratio (P/S) is 10.18 on February 02, 2024, which is -13.96% below the current Price to Sales Ratio (P/S).
Jiangsu Hengrui Medicine Co., Ltd. average Price to Sales Ratio (P/S) for the last 52 weeks is 12.42.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

Shanghai Stock Exchange: 600276.SS

Jiangsu Hengrui Medicine Co., Ltd.

CEO	Mr. Hong Bin Dai
IPO Date	Oct. 18, 2000
Location	China
Headquarters	38 Huanghe Rd Eco & Tech Dev Park
Employees	19,611
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Jiangsu Hengrui Medicine Co., Ltd., a pharmaceutical company, researches, develops, manufactures, and commercializes medicine worldwide. The company is developing Apatinib, Pyrotinib, Mecapegfilgrastim, SHR3680, SHR3162, SHR9549, SHR2554, SHR1459, SHR-1309, SHR-A1201, Camrelizumab, Famitinib, SHR-1316, SHR-1501, SHR-1603, SHR-1701, SHR-1702, and SHR-A1403 for oncology, metabolic, pain, autoimmune, and other indications. The company was founded in 1970 and is based in Lianyungang, China.

Key trends

Past 5 years